Drug Profile
SEL 403
Alternative Names: LMB 100/SVP Rapamycin; LMB-100/SEL-110; SEL-403; SVP Rapamycin/LMB 100Latest Information Update: 05 Dec 2023
Price :
$50
*
At a glance
- Originator Selecta Biosciences
- Developer Cartesian Therapeutics
- Class Anti-infectives; Antifungals; Antineoplastics; Immunotoxins; Lactones; Macrolides; Polyenes; Proteins; Pyridines; Recombinant fusion proteins
- Mechanism of Action Immunosuppressants; Megakaryocyte potentiating factor inhibitors; Methylmalonyl CoA mutase stimulants; MTOR protein inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- No development reported Mesothelioma
Most Recent Events
- 28 Mar 2021 No recent reports of development identified for phase-I development in Mesothelioma(In the elderly, Second-line therapy or greater, In adults) in USA (Parenteral)
- 03 Jan 2019 Suspended - Phase-I for Mesothelioma (In the elderly, Second-line therapy or greater, In adults) in USA (Parenteral)
- 03 Jan 2019 The US FDA puts clinical hold on phase I trial in Mesothelioma (NCT03436732)